Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results In a Q&A, Najat Khan explains what she believes sets the company apart in a crowded field

https://www.statnews.com/2025/11/21/recursion-ai-drug-development-najat-khan/